Table 2.
Patient Treatment Characteristics by colony-stimulating factor (CSF) use
| CSF status |
||||
|---|---|---|---|---|
| Characteristics | Total (N=13,203) |
No CSF (N=7,937; 60%) |
Primary CSF (N=1,339; 10%) |
Secondary CSF (N=3,927; 30%) |
| CSF use | ||||
| None | 7,937 (60.1%) | - | - | |
| G-CSF | 4,581 (34.7) | 1,198 (89.5%) | 3,383 (86.1%) | |
| GM-CSF | 316 (2.4) | 57 (4.3) | 259 (6.6) | |
| Both | 369 (2.8) | 84 (6.3) | 285 (7.3) | |
| Number of Administrations | ||||
| None | 7,937 (60.1) | - | - | |
| <5 | 1,588 (12.0) | 425 (31.7) | 1,163 (29.6) | |
| 5–14 | 1,627 (12.3) | 408 (30.5) | 1,219 (31.0) | |
| 15–24 | 837 (6.3) | 197 (14.7) | 640 (16.3) | |
| 25+ | 1,214 (9.2) | 309 (23.1) | 905 (23.0) | |
| Chemotherapy Agent | ||||
| Alkylating | 10,951 (82.9) | 6,100 (76.9%) | 1,215 (90.7) | 3,636 (92.6) |
| Topo-isomerase II inhibitors | 3,328 (25.2) | 1,600 (20.2) | 397 (29.6) | 1,331 (33.9) |
| Anthracyclines | 7,068 (53.5) | 3,550 (44.7) | 928 (69.3) | 2,590 (66.0) |
| Antimetabolites | 3,148 (23.8) | 1,581 (19.9) | 335 (25.0) | 1,232 (31.4) |
| Platinums | 520 (3.9) | 162 (2.0) | 79 (5.9) | 279 (7.1) |
| Taxanes | 132 (1.0) | 47 (0.6) | 20 (1.5) | 65 (1.7) |
| Vinca Alkaloids | 10,718 (81.2) | 5,964 (75.1) | 1,196 (89.3) | 3,558 (90.6) |
| Non-anthracycline antibiotics | 711 (5.4) | 419 (5.3) | 72 (5.4) | 220 (5.6) |
| Targeted (Biologics) | 6,937 (52.5) | 3,931 (49.5) | 746 (55.7) | 2,260 (57.6) |
| Other | 1,941 (14.7) | 1,144 (14.4) | 191 (14.3) | 606 (15.4) |
| Number of Chemotherapy DOS | ||||
| Mean (SD) | 18.9 (23.1) | 13.1 (14.9) | 23.4 (26.3) | 29.1 (30.5) |
| Median (Range) | 11 (1 – 394) | 8 (1 – 212) | 14 (1 – 273) | 19 (1 – 394) |
| Radiation Therapy | ||||
| No | 8,194 (62.1) | 5,069 (63.9) | 789 (58.9) | 2,336 (59.5) |
| Yes | 5,009 (37.9) | 2,868 (36.1) | 550 (41.1) | 1,591 (40.5) |